Given the relatively small number of patients with Huntington’s disease, a neurodegenerative genetic disorder, interest in this field from leading pharma players has been limited. However, with a genetic test available for this disorder, a shift in thinking towards niche conditions, and developments in the understanding of the disease, Huntington’s has the potential to become a lucrative market.

(more…)